MA03.02 TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

Datopotamab deruxtecan (Dato-DXd) is an antibody drug conjugate (ADC) composed of a TROP2-directed monoclonal antibody conjugated to a topoisomerase I inhibitor via a tetrapeptide-based cleavable linker. Dato-DXd demonstrated encouraging antitumor activity in patients with advanced/metastatic non-small cell lung cancer (NSCLC) in preliminary analyses from TROPION-PanTumor01. Based on this study, Dato-DXd 6 mg/kg has been selected as the recommended dose for the phase 3 TROPION-Lung01 trial. Here we report updated results in NSCLC.